Two drugs – Pfizer and Merck KGaA’s Bavencio and AstraZeneca’s Imfinzi – saw Phase III trials fail, while anticipated negative results prompted Roche to withdraw Tecentriq from regulatory review.
Article Source: Three PD-L1 inhibitors see setbacks in their development.
0 Comments